FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths

18th September 2017 Uncategorised 0

Keytruda’s stumble in multiple myeloma has hit another of its peers. Roche said Friday that, because of deaths in Keytruda’s combo trials with Celgene meds, the FDA put a partial hold on certain Tecentriq studies so it can assess the situation.

More: FDA slaps enrollment hold on 2 Tecentriq studies after Keytruda myeloma trial deaths
Source: fierce